RTP Mobile Logo
Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders (Video Program)
Released July 2017

Proceedings from a roundtable discussion with clinical investigators Drs Rafael Fonseca and Noopur Raje featuring the latest research developments in the management of multiple myeloma. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of hematologic cancers.

    Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancer and carries with it one of the worst death to new cases ratios. Although MM only represents 1.4% of all new cancer cases diagnosed in the United States, it would be difficult to identify another area of oncology in which the research database — and related treatment implications — has evolved more rapidly during the past decade. Featuring information on the latest research developments along with expert perspectives, this CME activity will deliver highly applicable, current clinical information delving into the individualized and multifaceted management of MM.


    • Develop a risk-adapted treatment plan for patients with smoldering MM, considering the roles of observation and active treatment.
    • Use patient- and disease-related factors, including cytogenetic profile, to customize the use of induction and maintenance therapeutic approaches in the transplant and nontransplant settings.
    • Consider available research data and other clinical factors in the best-practice selection, sequencing and combining of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory MM.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with recently approved systemic therapies to support quality of life and continuation of treatment.
    • Identify ongoing trials of investigational approaches in MM, and refer appropriate patients and obtain consent for study participation.

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis, Sanofi Genzyme, Takeda Oncology.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Celgene Corporation, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Celgene Corporation and Janssen Biotech Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 19, 2017
    Expiration date: July 19, 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Diagnosis and management of smoldering myeloma

  • Case discussion: A 64-year-old woman with monoclonal gammopathy of undetermined significance (MGUS) undergoes monitoring over time that reveals a slight increase in protein levels
  • QuiRedex: Results of a Phase III trial of lenalidomide/dexamethasone versus observation for high-risk smoldering myeloma
  • Phase II trial of elotuzumab/lenalidomide/dexamethasone for high-risk smoldering multiple myeloma (MM)

Induction, consolidation and maintenance therapy for MM

  • Case discussion: An 87-year-old man initially diagnosed with smoldering myeloma presents with progressive disease and receives lenalidomide/bortezomib/dexamethasone (RVd lite) followed by maintenance lenalidomide
  • Duration of therapy and activity of RVD lite in an 87-year-old man with symptomatic MM
  • Emergence of ixazomib as a component of induction and maintenance therapy for MM
  • Triplet versus doublet induction therapy for MM
  • IFM/DFCI 2009: Results of a Phase III trial evaluating immediate versus delayed autologous stem cell transplant after induction therapy for MM

Treatment of relapsed/refractory MM

  • Case discussion: A 76-year-old man with relapsed/refractory MM receives pomalidomide with daratumumab
  • Daratumumab efficacy and associated infusion reactions in patients with relapsed/refractory MM
  • Results of Phase III studies of daratumumab in combination with lenalidomide/dexamethasone (POLLUX) or with bortezomib/dexamethasone (CASTOR) for relapsed/refractory MM
  • Case discussion: A 45-year-old man with relapsed/refractory MM receives daratumumab with lenalidomide/dexamethasone
  • Activity and tolerability of daratumumab-based regimens for relapsed/refractory MM
  • Subcutaneous delivery of daratumumab for patients with relapsed/refractory MM
  • Re-treatment with IMiD-based regimens and/or monoclonal antibodies for patients with IMiD-refractory disease
  • Activity of the anti-CD38 monoclonal antibody isatuximab (SAR650984) in relapsed/refractory MM

Novel approaches under investigation for MM

  • Activity of the Bcl-2 inhibitor venetoclax alone and in combination with bortezomib/dexamethasone for patients with MM and 11;14 translocation
  • Incidence of venetoclax-associated tumor lysis syndrome in MM
  • Efficacy of checkpoint inhibitors for relapsed/refractory MM
  • Emerging research with CAR-T (chimeric antigen receptor T-cell) therapy